Oxaliplatin for Colorectal Cancer: 77 Real Stories

77 stories match colorectal cancer and oxaliplatin. 69 of them mention surgery.

Patricia, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Patricia's Patient Story

Patient Info: Patricia, 50s | Stage IV

Living with Stage IV colorectal cancer after about 6.5 years of intermittent chemotherapy and multiple local treatments; on a treatment holiday while awaiting December 2024 scans.

Our Cancer Stories
OutcomeLiving With Cancer
A patient, who was diagnosed with Colorectal CancerColorectal Cancer

Metastatic Colorectal Cancer Treated With S-1 After 5-FU Cardiotoxicity

Patient Info: Anonymized, male, 60s

Biomarkers: RAS-mutant

After progression in the liver despite prior systemic and liver-directed treatment, he started S-1, oxaliplatin and bevacizumab; the first cycle caused no cardiac complication and treatment continued as an outpatient.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colon Cancer With Tumor Thrombus Extending Into the Right Atrium

Patient Info: Anonymized, female, 40s

Biomarkers: BRAF wild-type, KRAS wild-type, NRAS wild-type

Her metastatic colorectal cancer progressed despite multiple treatment lines. Supportive care alone was chosen after her performance status deteriorated, and she later died from multiorgan failure in the setting of metastatic cancer.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Sigmoid colon cancer with later inguinal lymph-node metastasis: surgery, FOLFOX, FOLFIRI, and cetuximab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: CEA was elevated at diagnosis and recurrence. Metastatic lymph node was CK20 positive/CK7 negative; EGFR mutation status not reported.

Metastatic Site: left inguinal lymph node

Apparently disease-free 8 months after surgical removal of the left inguinal lymph-node metastasis followed by FOLFIRI plus cetuximab.

PubMed Central
OutcomeCancer-Free / NED